University of Pennsylvania

The Scripps Research Institute

Novartis Ag

University of Florida Research Foundation, Incorporated

Keio University

Vetigenics, Inc.

Donald L Siegel

Christoph Rader

Vijay Bhoj

Nathalie Scholler

George Coukos

Aizhi Zhao

John R Stanley

Michael C Milone

Aimee S Payne

Rebecca Goydel

Carlos F Barbas, Iii

Ken Ishii

Eric Michael Ostertag

Vladimir R Muzykantov

Nicola Mason

Xianxin Hua

Carlos H Villa

Xin He

X Long Zheng

Jun Yamagami

Amagai Masayuki

Stephen Kacir

Colin Greineder

Zijie Feng

Nicholas Chester

Carlos F Iii Barbas

The present invention includes compositions and methods for retrieving tumor-related antibodies and antigens. In one aspect, the invention includes a method for Sequential Tumor-related Antibody and antigen Retrieving (STAR) which directly and efficiently identifies potent antibodies that can specifically bind to tumor-related antigens on the tumor cell surface. In another aspect, the invention includes a CAR comprising a nanobody, a transmembrane domain, and an intracellular domain, wherein the nanobody is retrieved by a STAR method. In another aspect, the invention includes a CAR T system that targets CD13 and treats acute myeloid leukemia. In another aspect, the invention includes a CAR T system and ADC that targets CDH17 and treats NETs and other types of tumors expressing this antigen, with tolerable toxicities.

Compositions and methods for retrieving tumor-related antibodies and antigens

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein α-receptor 4 (GFRα4).

Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)

The present invention relates to canine antibodies, binding polypeptides, and scFvs specific for canine cytotoxic T lymphocyte associated protein 4 (CTLA-4).

Canine monoclonal antibodies against canine cytotoxic T lymphocyte associated protein 4 (CTLA-4)

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4).

Treatment of cancer using GFR alpha-4 chimeric antigen receptor

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein &#x3b1;-receptor 4 (GFR&#x3b1;4).

Compositions and methods are provided for loading cargoes onto red blood cells. Provided herein are novel antibodies, fragments, fusion proteins and other conjugates which specifically bind red blood cells via RHCE or Band 3.

Fusion proteins and antibodies targeting human red blood cell antigens

The present invention relates to compositions and methods of use of anti-ADAMTS13 autoantibodies and fragments thereof. In one aspect, the invention includes a composition comprising an isolated anti-ADAMTS13 autoantibody or fragment thereof. In other aspects, methods are described for generating an in vivo model of thrombotic thrombocytopenic purpura (TTP) comprising introducing at least one anti-ADAMTS13 autoantibody or fragment thereof into a model organism and identifying an anti-autoimmune reagent for treating TTP.

Human monoclonal autoantibodies to ADAMTS13 and uses thereof

The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Anti-TEM1 antibodies and uses thereof

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family &#x3b1;-receptor 4 (GFR&#x3b1;4).

Treatment of cancer using GFR &#x3b1;-4 chimeric antigen receptor

The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the 'receptor') is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the 'ligand' or &#x201c;target&#x201d;). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting marker molecule associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a marker molecule associated with the phage. In one aspect, the phenotype of the phage is not linked with the genotype of the phage.

Phage particle diagnostic reagents

The invention relates to Anti-TEM 1 anti-bodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.

Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies

The invention includes methods of isolating a multi-subunit protein which binds to an antigen-bearing moiety. The methods comprise generating a phage display library comprising a plurality of virus vectors.

Methods for isolation of antibody binding to cells

The present invention relates to novel methods for detecting at least one member of a known binding pair in a sample, including a cell, where one member of the pair (termed the 'receptor') is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the 'ligand' or &#x201c;target&#x201d;). Rather than detecting the binding of at least one phage using antibody-based technology, the present invention relates to detecting the nucleic acid associated with the phages. In one aspect, the invention relates to identifying at least one antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophages, using antiglobulin reagent-displaying bacteriophages and detecting at least one nucleic acid associated with the phage.

Growing community of inventors

Hatboro, PA, United States of America

Donald L Siegel